PMID- 32218819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - Upregulation of microRNA-31 is associated with poor prognosis in patients with 
      advanced colorectal cancer.
PG  - 2685-2694
LID - 10.3892/ol.2020.11365 [doi]
AB  - Colorectal cancer (CRC) manifests after the accumulation of genetic and 
      epigenetic alterations along with tumor microenvironments. MicroRNA (miRNA/miR) 
      molecules have been revealed to serve in critical roles in the progression 
      various types of cancer, and their expression level is often an important 
      diagnostic, predictive or prognostic biomarker. The aim of the present study was 
      to evaluate the potential of miRNAs as prognostic biomarkers for patients with 
      advanced CRC. miRNA arrays were performed on CRC specimens obtained from tumors 
      with various molecular statuses [e.g. KRAS proto-oncogene, GTPase (KRAS)/B-Raf 
      proto-oncogene, serine/threonine kinase (BRAF)/microsatellite instability (MSI)], 
      and their paired normal mucosal specimens. The miRNA array revealed that 
      miR-31-5p (miR-31) was specifically upregulated in CRCs with the BRAF V600E 
      mutation, the results of which were supported by subsequent analysis of a dataset 
      retrieved from The Cancer Genome Atlas (TCGA) database, which contained 
      information regarding 170 patients with CRC including 51 BRAF-mutant CRCs. Of our 
      cohort of 67 patients with stage IV CRC, 15 (22%) and 4 (6%) showed KRAS and BRAF 
      V600E mutations, respectively. Since the median miR-31 expression was 3.45 
      (range, 0.004-6330.531), the cut-off value was chosen as 3.5, and all tumors were 
      categorized into two groups accordingly (high-/low-miR-31 expression). The high 
      miR-31 expression group (n=33) was significantly associated with a poorer 
      mortality (univariate hazard ratio=2.12; 95% confidence interval, 0.23-0.95; 
      P=0.03) and exhibited a shorter median survival time (MST; 20.1 months) compared 
      with the low miR-31 expression group (n=34) (MST, 38.3 months; P=0.03), 
      indicating that miR-31 is a promising prognostic biomarker for patients with 
      advanced CRC. Thus, performing a functional analysis of miR-31 expression may 
      lead to the development of new targeted therapies for the various genetic 
      subtypes of CRC.
CI  - Copyright: (c) Kubota et al.
FAU - Kubota, Nobuhito
AU  - Kubota N
AD  - Department of Gastroenterological Surgery, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Taniguchi, Fumitaka
AU  - Taniguchi F
AD  - Department of Gastroenterological Surgery, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Nyuya, Akihiro
AU  - Nyuya A
AD  - Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Okayama 
      701-0192, Japan.
FAU - Umeda, Yuzo
AU  - Umeda Y
AD  - Department of Gastroenterological Surgery, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Mori, Yoshiko
AU  - Mori Y
AD  - Department of Gastroenterological Surgery, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Fujiwara, Toshiyoshi
AU  - Fujiwara T
AD  - Department of Gastroenterological Surgery, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
FAU - Tanioka, Hiroaki
AU  - Tanioka H
AD  - Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Okayama 
      701-0192, Japan.
FAU - Tsuruta, Atsushi
AU  - Tsuruta A
AD  - Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama 
      701-0192, Japan.
FAU - Yamaguchi, Yoshiyuki
AU  - Yamaguchi Y
AD  - Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Okayama 
      701-0192, Japan.
FAU - Nagasaka, Takeshi
AU  - Nagasaka T
AD  - Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Okayama 
      701-0192, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200203
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7068240
OTO - NOTNLM
OT  - BRAF
OT  - colorectal cancer
OT  - microRNA
OT  - microRNA-31
OT  - prognostic biomarker
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/02/03
CRDT- 2020/03/29 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/02/03 00:00 [pmc-release]
AID - OL-0-0-11365 [pii]
AID - 10.3892/ol.2020.11365 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Apr;19(4):2685-2694. doi: 10.3892/ol.2020.11365. Epub 2020 Feb 
      3.